The association between transfusion and cancer-free survival after curative resection for hepatocellular carcinoma

Cancer. 1993 Sep 15;72(6):1866-71. doi: 10.1002/1097-0142(19930915)72:6<1866::aid-cncr2820720613>3.0.co;2-f.

Abstract

Background: In cases of surgery for hepatocellular carcinoma (HCC), postoperative intrahepatic recurrence is the main obstacle to long-term survival of patients. The association between perioperative transfusion and recurrence-free survival was studied in 126 patients with HCC who underwent hepatic resection between 1985 and 1990 and in whom complete follow-up information was available until 1992.

Methods: Patients who received neither whole blood nor packed erythrocytes during hospitalization formed the no transfusion group (n = 72), and the remaining patients who were given either whole blood or packed erythrocytes during hospitalization constituted the transfusion group (n = 54).

Results: The 1-year, 3-year, and 5-year recurrence-free survival rates of the nontransfused versus transfused groups were 80.6% versus 74.1%, 50.9% versus 33.4%, and 37.1% versus 26.2%, respectively (P = 0.1590). After adjustment for other covariates, the serum albumin level and histological intrahepatic metastasis (im) remained as significant variables for recurrence-free survival. Although there was no association between the erythrocyte transfusion and the recurrence-free survival of the patients with serum albumin levels either more than 3.5 g/dl or less than or equal to 3.5 g/dl, the 1-year, 3-year, and 5-year recurrence-free survival rates of the nontransfused versus transfused groups of the patients with im-negative HCC were 92.2% versus 80.0%, 62.6% versus 36.3%, and 47.4% versus 27.1%, respectively (P = 0.0254).

Conclusions: The association between erythrocyte transfusion and the recurrence-free survival was recognized only in patients with im-negative HCC.

MeSH terms

  • Adult
  • Aged
  • Blood Transfusion*
  • Carcinoma, Hepatocellular / surgery*
  • Carcinoma, Hepatocellular / therapy
  • Female
  • Humans
  • Intraoperative Period
  • Liver Neoplasms / surgery*
  • Liver Neoplasms / therapy
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Regression Analysis
  • Time Factors